Vaccinations: cost effectiveness of strategies to increase coverage

Added June 9, 2020

Citation: Jacob V, Chattopadhyay SK, Hopkins DP, et al. Increasing Coverage of Appropriate Vaccinations: A Community Guide Systematic Economic Review. American Journal of Preventive Medicine. 2016;50(6):797‐808.

Free to view: No

What is this? The COVID-19 pandemic has placed a strain on healthcare services and resources. Existing evidence on the cost effective delivery of health care, such as vaccination programmes, might provide useful information for policy makers.

In this systematic review, the authors searched for economic evaluations of 12 strategies to increase vaccination coverage, as recommended by Community Preventive Task Force, USA, in three broad categories (those that enhance access to vaccinations, those that increase demand for vaccination and those that target the provider). They restricted their search to studies from high-income countries which were published in English and did the search in February 2012. They included 84 studies.

What was found: Strategies such as reminder systems targeted to clients and providers showed lower cost to implement and lower cost per additional person vaccinated.

Strategies based on home visits and combination strategies in community settings showed higher cost to implement and higher cost to vaccinate an additional person.

Strategies designed to reach large segments of a target population, such as those based in schools and women, infants and children (WIC) programmes showed relatively higher cost to implement but were able to vaccinate large numbers at a cost in the middle range of cost effectiveness. Schools and WIC settings may also help to reach children who might otherwise be unvaccinated, under-immunized or underserved.

The cost effectiveness of strategies for rural areas and for low-to-middle income countries are uncertain.

The cost effectiveness of requiring vaccination for school attendance is uncertain.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.